Has Ayanna Swinton Jamison, MD received payments from drug or device companies?

Yes. Drug and device makers reported $896 in general payments to Ayanna Swinton Jamison, MD across 35 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ayanna Swinton Jamison, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ayanna Swinton Jamison, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ayanna Swinton Jamison, MD

Child & Adolescent Psychiatry · Columbia, SCNPI 1053359851

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Amgen at 27.1% of the total. 2025 is the largest year on record at $499, 6.4 times the $78 reported in 2019.

$896in general payments, 2019–2025

Across 35 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$243
Supernus Pharmaceuticals, Inc.$145
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$93
Sunovion Pharmaceuticals Inc.$75
Idorsia Pharmaceuticals US Inc$71
Collegium Pharmaceutical, Inc.$50
plus $219 from 8 others

What the payments were for

Food & beverage$896100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	2	$243
Supernus Pharmaceuticals, Inc.	7	$145
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$93
Sunovion Pharmaceuticals Inc.	4	$75
Idorsia Pharmaceuticals US Inc	4	$71
Collegium Pharmaceutical, Inc.	2	$50
Neos Therapeutics, LP	2	$48
Johnson & Johnson	3	$44
Lundbeck LLC	2	$39
Takeda Pharmaceuticals U.S.A., Inc.	1	$21
Axsome Therapeutics, Inc.	1	$19
Ironshore Pharmaceuticals Inc.	1	$18
Otsuka America Pharmaceutical, Inc.	1	$15
Corium, LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

UPLIZNA$121

How this compares

$896 in reported general payments places this provider in the 70th percentile of 71 child & adolescent psychiatry providers in South Carolina.

See all child & adolescent psychiatry providers in South Carolina →

Medicare billing

Part B allowed, 2024

$16,466

Medicare patients

Services billed

191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VraylarCariprazine Hcl	38	$53,498
FanaptIloperidone	13	$50,399
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	220	$6,446
Aripiprazole	93	$4,759
Alprazolam	300	$1,915
Clonazepam	117	$1,888
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	47	$1,268
Bupropion XlBupropion Hcl	105	$1,216
Duloxetine Hcl	99	$1,182
Quetiapine Fumarate	100	$1,086
Hydroxyzine Pamoate	54	$821
Venlafaxine Hcl ErVenlafaxine Hcl	86	$748
Zolpidem Tartrate	115	$687
Mirtazapine	54	$508
Escitalopram Oxalate	86	$464

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Columbia

Don DuboseColumbia$290K
Elizabeth JeffordsColumbia$5K
Isabella AdjinahColumbia$583
Seth LapicColumbia$240
Ashleigh Quick LedfordColumbia$167
Elizabeth BakerColumbia$138
Michelle WidenerColumbia$125
Craig StuckColumbia$120
James ClaytorColumbia$71
Jennifer HeathColumbia$63

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →